Boao Conference On Real World Studies Wraps Up With Over 800 Participants

KUALA LUMPUR, Dec 2 (Bernama) -- The third Boao International Conference on Real World Studies of Medical Products concluded successfully last month in Boao, Hainan Province, China with over 800 participants, including international organisations representatives, regulatory agencies for drugs and medical devices, and prominent medical institutions.

Real-world studies (RWS), in recent years, have garnered widespread attention from regulatory agencies worldwide for their critical role in the evaluation and approval of drugs and medical devices, while real-world data has increasingly been recognised as a key resource in supporting regulatory decision-making globally.

Organised by the Hainan Lecheng Institute of Real World Study, the conference focused on the theme "Real-World Studies Facilitate Clinical Evaluation of Innovative Drugs and Medical Devices". It served as a vital platform for sharing regulatory science insights and showcasing advanced research, fostering industry growth.

bootstrap slideshow

According to a statement, the programme featured a plenary session and seven thematic sessions covering topics such as RWS and clinical evaluation of drugs; RWS and clinical evaluation of medical devices; RWS and pharmacovigilance; RWS and biostatistics; and RWS and information technologies.

China’s only "medical special zone" and the country's first pilot area for the application of real-world data, the Boao Lecheng International Medical Tourism Pilot Zone is committed to becoming a world-class international medical tourism destination and a hub for medical technology innovation.

Since the launch of the clinical real-world data application pilot programme in 2019 by the Hainan Provincial People’s Government and National Medical Products Administration (NMPA), the Boao conference has emerged as a key platform for global collaboration and resource sharing in RWS.

bootstrap slideshow

The conference has featured contributions from the World Health Organization (WHO) and the Council for International Organizations of Medical Sciences (CIOMS), along with regulatory agencies. In addition, experts from research institutions and multinational pharmaceutical and medical device companies have also shared cutting-edge research results and regulatory advancements in the field at the event.

Over the past five years, 40 international innovative drugs and medical devices have been studied in the pilot zone using real-world data. Of these, 17 products, including five drugs and 12 medical devices, have received approval for market entry in China.

At present, the Lecheng zone has built partnerships with over 170 pharmaceutical and medical device companies worldwide, introducing more than 440 urgently needed imported products.

Meanwhile, at the concurrent Lecheng Business Development Conference, over 100 innovative products online from China and abroad were unveiled, accelerating the industrialisation of new medical advancements and enabling biopharmaceutical companies access to China's expanding wellness market.

-- BERNAMA